Cargando…
Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy
SIMPLE SUMMARY: Skull-base chondrosarcoma is a rare locally aggressive or malignant group of cartilaginous neoplasm. The standard of care consists of surgery and high-dose radiation therapy, better if with particle, due to their radioresistance and proximity to organs at risk such as brainstem and o...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430859/ https://www.ncbi.nlm.nih.gov/pubmed/34503233 http://dx.doi.org/10.3390/cancers13174423 |
_version_ | 1783750802980995072 |
---|---|
author | Riva, Giulia Cavallo, Iacopo Gandini, Sara Ingargiola, Rossana Pecorilla, Mattia Imparato, Sara Rossi, Eleonora Mirandola, Alfredo Ciocca, Mario Orlandi, Ester Iannalfi, Alberto |
author_facet | Riva, Giulia Cavallo, Iacopo Gandini, Sara Ingargiola, Rossana Pecorilla, Mattia Imparato, Sara Rossi, Eleonora Mirandola, Alfredo Ciocca, Mario Orlandi, Ester Iannalfi, Alberto |
author_sort | Riva, Giulia |
collection | PubMed |
description | SIMPLE SUMMARY: Skull-base chondrosarcoma is a rare locally aggressive or malignant group of cartilaginous neoplasm. The standard of care consists of surgery and high-dose radiation therapy, better if with particle, due to their radioresistance and proximity to organs at risk such as brainstem and optic pathways. Due to the rarity of the tumor and its site, outcomes in terms of local control and toxicity of patients with this malignancy after receiving particle therapy has been documented only in a limited number of series with a restricted number of patients, in particular with regard to carbon ions. The aim of our retrospective study is to assess the role of particle therapy (protons and carbon ions) after surgery in our Institute in skull-base chondrosarcomas. ABSTRACT: Background: The standard treatment for skull base chondrosarcoma (SB-CHS) consists of surgery and high-dose radiation therapy. Our aim was to evaluate outcome in terms of local control (LC) and toxicity of proton therapy (PT) and carbon ion (CIRT) after surgery. Materials and methods: From September 2011 to July 2020, 48 patients underwent particle therapy (67% PT, 33% CIRT) for SB-CHS. PT and CIRT total dose was 70 GyRBE (relative biological effectiveness) in 35 fractions and 70.4 GyRBE in 16 fractions, respectively. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5). Results: After a median follow-up time of 38 months, one local failure (2%) was documented and the patient died for progressive disease. Overall, 3-year LC was 98%. One (2%) and 4 (8%) patients experienced G3 acute and late toxicity, respectively. White-matter brain changes were documented in 22 (46%) patients, but only 7 needed steroids (G2). No patients had G3 brain toxicity. No G4–5 complications were reported. We did not find any correlation between high-grade toxicity or white-matter changes and characteristics of patients, disease and surgery. Conclusions: PT and CIRT appeared to be effective and safe treatments for patients with SB-CHS, resulting in high LC rates and an acceptable toxicity profile. |
format | Online Article Text |
id | pubmed-8430859 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84308592021-09-11 Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy Riva, Giulia Cavallo, Iacopo Gandini, Sara Ingargiola, Rossana Pecorilla, Mattia Imparato, Sara Rossi, Eleonora Mirandola, Alfredo Ciocca, Mario Orlandi, Ester Iannalfi, Alberto Cancers (Basel) Article SIMPLE SUMMARY: Skull-base chondrosarcoma is a rare locally aggressive or malignant group of cartilaginous neoplasm. The standard of care consists of surgery and high-dose radiation therapy, better if with particle, due to their radioresistance and proximity to organs at risk such as brainstem and optic pathways. Due to the rarity of the tumor and its site, outcomes in terms of local control and toxicity of patients with this malignancy after receiving particle therapy has been documented only in a limited number of series with a restricted number of patients, in particular with regard to carbon ions. The aim of our retrospective study is to assess the role of particle therapy (protons and carbon ions) after surgery in our Institute in skull-base chondrosarcomas. ABSTRACT: Background: The standard treatment for skull base chondrosarcoma (SB-CHS) consists of surgery and high-dose radiation therapy. Our aim was to evaluate outcome in terms of local control (LC) and toxicity of proton therapy (PT) and carbon ion (CIRT) after surgery. Materials and methods: From September 2011 to July 2020, 48 patients underwent particle therapy (67% PT, 33% CIRT) for SB-CHS. PT and CIRT total dose was 70 GyRBE (relative biological effectiveness) in 35 fractions and 70.4 GyRBE in 16 fractions, respectively. Toxicity was assessed using the Common Terminology Criteria for Adverse Events (CTCAE v5). Results: After a median follow-up time of 38 months, one local failure (2%) was documented and the patient died for progressive disease. Overall, 3-year LC was 98%. One (2%) and 4 (8%) patients experienced G3 acute and late toxicity, respectively. White-matter brain changes were documented in 22 (46%) patients, but only 7 needed steroids (G2). No patients had G3 brain toxicity. No G4–5 complications were reported. We did not find any correlation between high-grade toxicity or white-matter changes and characteristics of patients, disease and surgery. Conclusions: PT and CIRT appeared to be effective and safe treatments for patients with SB-CHS, resulting in high LC rates and an acceptable toxicity profile. MDPI 2021-09-02 /pmc/articles/PMC8430859/ /pubmed/34503233 http://dx.doi.org/10.3390/cancers13174423 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Riva, Giulia Cavallo, Iacopo Gandini, Sara Ingargiola, Rossana Pecorilla, Mattia Imparato, Sara Rossi, Eleonora Mirandola, Alfredo Ciocca, Mario Orlandi, Ester Iannalfi, Alberto Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy |
title | Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy |
title_full | Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy |
title_fullStr | Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy |
title_full_unstemmed | Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy |
title_short | Particle Radiotherapy for Skull Base Chondrosarcoma: A Clinical Series from Italian National Center for Oncological Hadrontherapy |
title_sort | particle radiotherapy for skull base chondrosarcoma: a clinical series from italian national center for oncological hadrontherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8430859/ https://www.ncbi.nlm.nih.gov/pubmed/34503233 http://dx.doi.org/10.3390/cancers13174423 |
work_keys_str_mv | AT rivagiulia particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT cavalloiacopo particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT gandinisara particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT ingargiolarossana particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT pecorillamattia particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT imparatosara particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT rossieleonora particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT mirandolaalfredo particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT cioccamario particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT orlandiester particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy AT iannalfialberto particleradiotherapyforskullbasechondrosarcomaaclinicalseriesfromitaliannationalcenterforoncologicalhadrontherapy |